Bertelsen C A, Korn E I, Morton D L, Kern D H
Arch Surg. 1983 Dec;118(12):1406-9. doi: 10.1001/archsurg.1983.01390120036010.
To determine whether in vitro chemosensitivities of clones from metastases of human tumors varied, biopsy specimens of two separate metastatic lesions were obtained from 75 patients. Significant tumor growth (greater than 30 colonies per plate) occurred in both specimens in 49 of the 75 patients. Biopsies were performed simultaneously in 22 patients (synchronous) and sequentially in 27 patients (metachronous). Tumor samples were scored as being resistant (less than 50% inhibition of colony formation) or sensitive (greater than 50% inhibition) to each drug. The two tumor samples from each patient were compared for differences in sensitivity after exposure with standard panels of chemotherapeutic agents. A total of 272 individual drug comparisons were possible. Variations were evident in 49 (40%) of 121 metachronous drug comparisons and in 42 (28%) of 151 synchronous drug comparisons. We concluded that multiple metastases of human tumors can vary in chemosensitivity in vitro; this finding seemed to reflect the heterogeneity of metastatic clones.
为了确定源自人类肿瘤转移灶的克隆的体外化学敏感性是否存在差异,我们从75例患者身上获取了两个独立转移病灶的活检标本。在75例患者中,有49例患者的两个标本均出现了显著的肿瘤生长(每平板大于30个集落)。22例患者同时进行活检(同步活检),27例患者依次进行活检(异时活检)。肿瘤样本被评定为对每种药物耐药(集落形成抑制率小于50%)或敏感(集落形成抑制率大于50%)。在使用标准化化疗药物组合处理后,比较了每位患者的两个肿瘤样本的敏感性差异。总共可以进行272次个体药物比较。在121次异时药物比较中有49次(40%)出现差异,在151次同步药物比较中有42次(28%)出现差异。我们得出结论,人类肿瘤的多个转移灶在体外化学敏感性上可能存在差异;这一发现似乎反映了转移克隆的异质性。